Sun, Apr 20, 2014, 12:32 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CombiMatrix Corporation Message Board

love2profit 2 posts  |  Last Activity: Feb 15, 2014 10:59 AM Member since: Oct 21, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This excerpt taken from the AEN 8-K filed Aug 14, 2008.
    TRIMESTA (oral, once-daily estriol)

    TRIMESTA, our oral, once-daily bioidentical hormone estriol is currently in a seven U.S. center, placebo-controlled Phase II/III clinical trial which is expected to enroll up to 150 relapsing-remitting Multiple Sclerosis (MS) patients. TRIMESTA is being supported under a $5 million grant from the Southern California Chapter of the National Multiple Sclerosis Society and NIH. Oral estriol, the active ingredient in TRIMESTA, has been approved throughout Europe and Asia for approximately 40 years but is not available in the U.S.

    This Phase II/III clinical trial builds upon our encouraging results from an earlier single agent Phase IIa clinical trial in female MS patients whereby TRIMESTA demonstrated a 79 percent decrease in MS brain lesions in 3 months (p=0.02) and a 14 percent improvement in cognitive function as measured by the PASAT scoring system at 6 months (p=0.04). This dataset is also supplemented by a definitive study of the effect of pregnancy on MS, known as the PRIMS (Rate of Pregnancy-related Relapse in Multiple Sclerosis) which was published in the New England Journal of Medicine (NEJM) by Confavreux et al. In that study, relapse rates were determined in 254 women with MS during pregnancy and for up to one year after delivery. Relapse rates were shown to be significantly reduced during the third trimester of pregnancy, by 71 percent (p

    Sentiment: Strong Buy

  • We may see Pertussis results before Trimestra...listen to the investor presentation from last week...it is excellent...this is mentioned near the end by CEO Riley

CBMX
2.605+0.005(+0.19%)Apr 17 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.